FGFR1 signaling potentiates tumor growth and predicts poor prognosis in esophageal squamous cell carcinoma patients

References

• Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108. doi:10.3322/caac.21262. PMID:25651787
   PubMed Web of Science ®Google Scholar
• Digklia A, Voutsadakis IA. Targeted treatments for metastatic esophageal squamous cell cancer. World J Gastrointest Oncol. 2013;5:88–96. doi:10.4251/wjgo.v5.i5.88. PMID:23799158
   PubMed Web of Science ®Google Scholar
• Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer. 2010;10:116–29. doi:10.1038/nrc2780. PMID:20094046
   PubMed Web of Science ®Google Scholar
• Grose R, Dickson C. Fibroblast growth factor signaling in tumorigenesis. Cytokine Growth Factor Rev. 2005;16:179–86. doi:10.1016/j.cytogfr.2005.01.003. PMID:15863033
   PubMed Web of Science ®Google Scholar
• Weeden CE, Solomon B, Asselin-Labat ML. FGFR1 inhibition in lung squamous cell carcinoma: questions and controversies. Cell Death Discov. 2015;1:15049. doi:10.1038/cddiscovery.2015.49. PMID:27551478
   PubMedGoogle Scholar
• Xie FJ, Lu HY, Zheng QQ, Qin J, Gao Y, Zhang YP, Hu X, Mao WM. The clinical pathological characteristics and prognosis of FGFR1 gene amplification in non-small-cell lung cancer: a meta-analysis. Onco Targets Ther. 2016;9:171–81. doi:10.2147/OTT.S91848. PMID:26793001
   PubMed Web of Science ®Google Scholar
• Wang Y, Gao W, Xu J, Chen X, Yang Y, Zhu Y, Yin Y, Guo R, Liu P, Shu Y, et al. The role of FGFR1 gene amplification as a poor prognostic factor in squamous cell lung cancer: a meta-analysis of published data. Biomed Res Int. 2015;2015:763080. doi:10.1155/2015/763080. PMID:26788508
   PubMedGoogle Scholar
• Heist RS, Mino-Kenudson M, Sequist LV, Tammireddy S, Morrissey L, Christiani DC, Engelman JA, Iafrate AJ. FGFR1 amplification in squamous cell carcinoma of the lung. J Thorac Oncol. 2012;7:1775–80. doi:10.1097/JTO.0b013e31826aed28. PMID:23154548
   PubMed Web of Science ®Google Scholar
• Kwon D, Yun JY, Keam B, Kim YT, Jeon YK. Prognostic implications of FGFR1 and MYC status in esophageal squamous cell carcinoma. World J Gastroenterol. 2016;22:9803–12. doi:10.3748/wjg.v22.i44.9803. PMID:27956804
   PubMed Web of Science ®Google Scholar
• Ach T, Schwarz-Furlan S, Ach S, Agaimy A, Gerken M, Rohrmeier C, Zenk J, Iro H, Brockhoff G, Ettl T. Genomic aberrations of MDM2, MDM4, FGFR1 and FGFR3 are associated with poor outcome in patients with salivary gland cancer. J Oral Pathol Med. 2016;45:500–9. doi:10.1111/jop.12394. PMID:26661925
   PubMed Web of Science ®Google Scholar
• Cheng CL, Thike AA, Tan SY, Chua PJ, Bay BH, Tan PH. Expression of FGFR1 is an independent prognostic factor in triple-negative breast cancer. Breast Cancer Res Treat. 2015;151:99–111. doi:10.1007/s10549-015-3371-x. PMID:25868865
   PubMed Web of Science ®Google Scholar
• Kim HS, Lee SE, Bae YS, Kim DJ, Lee CG, Hur J, Chung H, Park JC, Jung DH, Shin SK, et al. Fibroblast growth factor receptor 1 gene amplification is associated with poor survival in patients with resected esophageal squamous cell carcinoma. Oncotarget. 2015;6:2562–72. doi:10.18632/oncotarget.2944. PMID:25537505
   PubMed Web of Science ®Google Scholar
• Wong AJ, Bigner SH, Bigner DD, Kinzler KW, Hamilton SR, Vogelstein B. Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. Proc Natl Acad Sci U S A. 1987;84:6899–903. doi:10.1073/pnas.84.19.6899. PMID:3477813
   PubMed Web of Science ®Google Scholar
• von Loga K, Kohlhaussen J, Burkhardt L, Simon R, Steurer S, Burdak-Rothkamm S, Jacobsen F, Sauter G, Krech T. FGFR1 amplification is often homogeneous and strongly linked to the squamous cell carcinoma subtype in esophageal carcinoma. PLoS One. 2015;10:e0141867. doi:10.1371/journal.pone.0141867. PMID:26555375
   PubMed Web of Science ®Google Scholar
• Shi YJ, Tsang JY, Ni YB, Chan SK, Chan KF, Tse GM. FGFR1 is an adverse outcome indicator for luminal A breast cancers. Oncotarget. 2016;7:5063–73. doi:10.18632/oncotarget.6563. PMID:26673008
   PubMed Web of Science ®Google Scholar
• Tomiguchi M, Yamamoto Y, Yamamoto-Ibusuki M, Goto-Yamaguchi L, Fujiki Y, Fujiwara S, Sueta A, Hayashi M, Takeshita T, Inao T, et al. Fibroblast growth factor receptor-1 protein expression is associated with prognosis in estrogen receptor-positive/human epidermal growth factor receptor-2-negative primary breast cancer. Cancer Sci. 2016;107:491–8. doi:10.1111/cas.12897. PMID:26801869
   PubMed Web of Science ®Google Scholar
• Pu D, Liu J, Li Z, Zhu J, Hou M. Fibroblast Growth Factor Receptor 1 (FGFR1), partly related to Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) and microvessel density, is an independent prognostic factor for non-small cell lung cancer. Med Sci Monit. 2017;23:247–57. doi:10.12659/MSM.899005. PMID:28088809
   PubMed Web of Science ®Google Scholar
• Yang F, Gao Y, Geng J, Qu D, Han Q, Qi J, Chen G. Elevated expression of SOX2 and FGFR1 in correlation with poor prognosis in patients with small cell lung cancer. Int J Clin Exp Pathol. 2013;6:2846–54. PMID:24294370
   PubMed Web of Science ®Google Scholar
• Sugiura K, Ozawa S, Kitagawa Y, Ueda M, Kitajima M. Co-expression of aFGF and FGFR-1 is predictive of a poor prognosis in patients with esophageal squamous cell carcinoma. Oncol Rep. 2007;17:557–64. PMID:17273733
   PubMed Web of Science ®Google Scholar
• Kim HR, Kim DJ, Kang DR, Lee JG, Lim SM, Lee CY, Rha SY, Bae MK, Lee YJ, Kim SH, et al. Fibroblast growth factor receptor 1 gene amplification is associated with poor survival and cigarette smoking dosage in patients with resected squamous cell lung cancer. J Clin Oncol. 2013;31:731–7. doi:10.1200/JCO.2012.43.8622. PMID:23182986
   PubMed Web of Science ®Google Scholar
• Eswarakumar VP, Lax I, Schlessinger J. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev. 2005;16:139–49. doi:10.1016/j.cytogfr.2005.01.001. PMID:15863030
   PubMed Web of Science ®Google Scholar
• Karajannis MA, Vincent L, Direnzo R, Shmelkov SV, Zhang F, Feldman EJ, Bohlen P, Zhu Z, Sun H, Kussie P, et al. Activation of FGFR1beta signaling pathway promotes survival, migration and resistance to chemotherapy in acute myeloid leukemia cells. Leukemia. 2006;20:979–86. doi:10.1038/sj.leu.2404203. PMID:16598308
   PubMed Web of Science ®Google Scholar
• Tomlinson DC, Lamont FR, Shnyder SD, Knowles MA. Fibroblast growth factor receptor 1 promotes proliferation and survival via activation of the mitogen-activated protein kinase pathway in bladder cancer. Cancer Res. 2009;69:4613–20. doi:10.1158/0008-5472.CAN-08-2816. PMID:19458078
   PubMed Web of Science ®Google Scholar
• Jiao J, Zhao X, Liang Y, Tang D, Pan C. FGF1-FGFR1 axis promotes tongue squamous cell carcinoma (TSCC) metastasis through epithelial-mesenchymal transition (EMT). Biochem Biophys Res Commun. 2015;466:327–32. doi:10.1016/j.bbrc.2015.09.021. PMID:26362179
   PubMed Web of Science ®Google Scholar
• Tomlinson DC, Baxter EW, Loadman PM, Hull MA, Knowles MA. FGFR1-induced epithelial to mesenchymal transition through MAPK/PLCgamma/COX-2-mediated mechanisms. PLoS One. 2012;7:e38972. doi:10.1371/journal.pone.0038972. PMID:22701738
   PubMed Web of Science ®Google Scholar
• Acevedo VD, Gangula RD, Freeman KW, Li R, Zhang Y, Wang F, Ayala GE, Peterson LE, Ittmann M, Spencer DM. Inducible FGFR-1 activation leads to irreversible prostate adenocarcinoma and an epithelial-to-mesenchymal transition. Cancer Cell. 2007;12:559–71. doi:10.1016/j.ccr.2007.11.004. PMID:18068632
   PubMed Web of Science ®Google Scholar
• Ji W, Yu Y, Li Z, Wang G, Li F, Xia W, Lu S. FGFR1 promotes the stem cell-like phenotype of FGFR1-amplified non-small cell lung cancer cells through the Hedgehog pathway. Oncotarget. 2016;7:15118–34. doi:10.18632/oncotarget.7701. PMID:26936993
   PubMed Web of Science ®Google Scholar
• Fillmore CM, Gupta PB, Rudnick JA, Caballero S, Keller PJ, Lander ES, Kuperwasser C. Estrogen expands breast cancer stem-like cells through paracrine FGF/Tbx3 signaling. Proc Natl Acad Sci U S A. 2010;107:21737–42. PMID:21098263
   PubMed Web of Science ®Google Scholar
• Ye T, Wei X, Yin T, Xia Y, Li D, Shao B, Song X, He S, Luo M, Gao X, et al. Inhibition of FGFR signaling by PD173074 improves antitumor immunity and impairs breast cancer metastasis. Breast Cancer Res Treat. 2014;143:435–46. PMID:24398778
   PubMed Web of Science ®Google Scholar
• Nguyen PT, Tsunematsu T, Yanagisawa S, Kudo Y, Miyauchi M, Kamata N, Takata T. The FGFR1 inhibitor PD173074 induces mesenchymal-epithelial transition through the transcription factor AP-1. Br J Cancer. 2013;109:2248–58. PMID:24045665
   PubMed Web of Science ®Google Scholar
• Saito S, Morishima K, Ui T, Hoshino H, Matsubara D, Ishikawa S, Aburatani H, Fukayama M, Hosoya Y, Sata N, et al. The role of HGF/MET and FGF/FGFR in fibroblast-derived growth stimulation and lapatinib-resistance of esophageal squamous cell carcinoma. BMC Cancer. 2015;15:82. PMID:25884729
   PubMed Web of Science ®Google Scholar
• Ye YW, Hu S, Shi YQ, Zhang XF, Zhou Y, Zhao CL, Wang GJ, Wen JG, Zong H. Combination of the FGFR4 inhibitor PD173074 and 5-fluorouracil reduces proliferation and promotes apoptosis in gastric cancer. Oncol Rep. 2013;30:2777–84. PMID:24126887
   PubMed Web of Science ®Google Scholar
• Nogova L, Sequist LV, Perez Garcia JM, Andre F, Delord JP, Hidalgo M, Schellens JH, Cassier PA, Camidge DR, Schuler M, et al. Evaluation of BGJ398, a fibroblast growth factor receptor 1–3 Kinase inhibitor, in patients with advanced solid tumors harboring genetic alterations in fibroblast growth factor receptors: results of a global Phase I, dose-escalation and dose-expansion study. J Clin Oncol. 2017;35:157–65. PMID:27870574
   PubMed Web of Science ®Google Scholar
• Tabernero J, Bahleda R, Dienstmann R, Infante JR, Mita A, Italiano A, Calvo E, Moreno V, Adamo B, Gazzah A, et al. Phase I Dose-escalation study of JNJ-42756493, an oral pan-fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors. J Clin Oncol. 2015;33:3401–8. PMID:26324363
   PubMed Web of Science ®Google Scholar
• Papadopoulos KP, Tolcher AW, Patnaik A, Rasco DW, Chambers G, Beeram M, et al. Phase 1, first-in-human study of ARQ 087, an oral pan-Fibroblast Growth Factor Receptor (FGFR) inhibitor, in patients (pts) with advanced solid tumors. J Clin Oncol. 2017;35:4017–4017. doi:10.1200/JCO.2017.35.15_suppl.4017.
   Google Scholar
• Smyth EC, Turner NC, Peckitt C, Pearson A, Brown G, Chua S, et al. Phase II multicenter proof of concept study of AZD4547 in FGFR amplified tumours. J Clin Oncol. 2015;33:2508–2508. doi:10.1200/jco.2015.33.15_suppl.2508.
   Web of Science ®Google Scholar
• Andre F, Ranson M, Dean E, Varga A, Van der Noll R, Stockman PK, et al. Abstract LB-145: Results of a phase I study of AZD4547, an inhibitor of fibroblast growth factor receptor (FGFR), in patients with advanced solid tumors. Cancer Res. 2013;73(8 Suppl):Abstract nr LB-145. doi:10.1158/1538-7445.AM2013-LB-145.
   Google Scholar
• Wynes MW, Hinz TK, Gao D, Martini M, Marek LA, Ware KE, Edwards MG, Böhm D, Perner S, Helfrich BA, et al. FGFR1 mRNA and protein expression, not gene copy number, predict FGFR TKI sensitivity across all lung cancer histologies. Clin Cancer Res. 2014;20:3299–309. doi:10.1158/1078-0432.CCR-13-3060. PMID:24771645
   PubMed Web of Science ®Google Scholar
• Goke F, Franzen A, Hinz TK, Marek LA, Yoon P, Sharma R, Bode M, von Maessenhausen A, Lankat-Buttgereit B, Göke A, et al. FGFR1 expression levels predict BGJ398 sensitivity of FGFR1-dependent head and neck squamous cell cancers. Clin Cancer Res. 2015;21:4356–64. doi:10.1158/1078-0432.CCR-14-3357. PMID:26015511
   PubMed Web of Science ®Google Scholar